Umit AKPINAR, Gunes Gur AKSOY, Yildiz HAYRAN, Esra Firat OGUZ, Akin AKTAS, Ekrem CIVAS, Berna AKSOY
Journal of Clinical Trials and Experimental Investigations - 2026;5(3):0-0
Objective: Previous studies have reported conflicting findings regarding the role of the IL-33/sST2 axis and circulating IL-33 and sST2 concentrations in psoriasis. This study aimed to evaluate serum IL-33 and sST2 concentrations in patients with psoriasis and controls. Materials and methods: The study included 75 patients with psoriasis and 75 age- and sex-matched controls with non-inflammatory dermatological conditions, all aged 18-65 years. Demographic and clinical characteristics and body mass index (BMI) were recorded, and disease severity was assessed using the Psoriasis Area and Severity Index (PASI). Serum IL-33 and sST2 concentrations were measured using ELISA. Results: Mean serum IL-33 concentrations were significantly lower in patients with psoriasis than in controls (153.9 +/- 59.7 vs. 157.8 +/- 34.4 pg/mL, p = 0.001). Median serum sST2 concentrations did not differ significantly between patients with psoriasis and controls (9.1 vs. 10.6 ng/mL, p = 0.74). IL-33 concentrations showed a positive correlation with age (r = 0.26, p = 0.007), whereas sST2 concentrations were higher in male than in female participants (11.2 vs. 7.8 ng/mL, p = 0.003). Conclusion: Lower circulating IL-33 concentrations were observed in patients with psoriasis, whereas sST2 concentrations did not differ significantly from those in controls. These findings suggest that circulating IL-33 may not directly reflect its local activity in psoriatic tissue. Tissue-specific regulation or limited systemic release may contribute to this discrepancy, although this hypothesis requires further investigation.